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INTRODUCTION
“Precision dosing” focuses on the individualization of drug
treatment regimens based on patient factors known to alter
drug disposition and/or response. In 2015, over 8 in 10 non-
federal acute care hospitals in the United States had adopted
a basic electronic health record (EHR) system,1 which will
facilitate the application of precision dosing. Expanding on
recent publications,2,3 we outline the public health need,
a proposed framework, and the anticipated impact for the
adoption of precision dosing.
THE NEED FOR PRECISION DOSING
The concept of “precision medicine” offers the hope of
optimizing disease prevention and treatment strategies by
taking into account factors that contribute to interindivid-
ual variability.4 During the drug development process, sev-
eral studies are performed using tools, such as pharma-
cokinetic/ pharmacodynamic (PK/PD) modeling, that collect
useful dosing information and help to identify patient sub-
groups most likely to benefit from a new drug. Furthermore,
genomic and nongenomic biomarker data may be used to
differentiate subgroups of patients with varying drug clear-
ance, exposure–response relationships, drug safety, and dis-
ease progression/severity.5,6 This rich information from early
development studies is used to inform phase III trial design,
as well as drug dosage regimen and patient selection for
these studies, and can be integral to the drug label (if the
drug is eventually approved).7
In the United States the Food and Drug Administra-
tion (FDA) performs rigorous statistical and pharmacometric
quantitative analyses to replicate the sponsor’s analyses, and
to understand better which patients will most likely receive
benefit from a new drug.8,9 Patient factors that may be con-
sidered include sex, body size, organ function, age, geno-
type, concomitant medications, and disease severity. The
FDA may choose to change labeled doses for certain sub-
groups (e.g., gender, renal function, age), based on either
the sponsor’s or their own PK/PD analyses, when the sup-
portive data are available. However, few options are avail-
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able if the sponsor chooses not to integrate biomarker data
into the design of the phase III trial. Furthermore, the dosage
regimen in the approved label will either indicate quantita-
tive or qualitative (e.g., increase/decrease) dose adjustments
based on patient factors known to alter the PK and/or PD of
the drug. However, it is relatively rare that dosage regimens
will be recommended for patients who present with multi-
ple characteristics known to alter drug disposition or efficacy
(e.g., decreased renal function plus a drug interaction plus a
polymorphic genotype). One notable example is the pack-
age insert Cerdelga (eliglustat) where dosing recommenda-
tions are provided as a function of both CYP2D6 metabo-
lizer status and the concomitant use of CYP3A and CYP2D6
inhibitors.10
Furthermore, when the pivotal clinical trial demonstrates
efficacy, the sponsor’s New Drug Application (NDA) to the
FDA may recommend very limited dose adjustments in the
label based on patient factors (e.g., renal function, genotype,
drug–drug interactions) or for special populations (e.g., pedi-
atrics, pregnancy/lactation, geriatrics), and rarely advocate
for clinical use of tools that integrate patient factors to help
facilitate dose individualization. A recent “State of the Art”
article extensively outlined the challenges that need to be
overcome in order for “model-informed precision dosing” to
be used routinely in healthcare practices in the future.2 Pre-
cision dosing in that previous article and the present article
refers to the optimization of drug dosing in individual patients
with the goal of maximizing efficacy and/or minimizing tox-
icity. Although it can be argued that “accurate dosing” may
be a more appropriate phrase, “precision dosing” has been
adopted by us and others2 in order to be consistent with the
widely accepted initiative focused on “precision medicine”
and because it is more likely to be understood by the public.
The use of precision dosing offers the potential to
overcome a common pattern observed in postregulatory
approval, where the benefit-to-risk relationship of a drug is
less favorable than what was reported in clinical trials.11 This
pattern is often due to greater diversity in the patients who
receive the drug postapproval, resulting in increased vari-
ability in drug exposure and response.11 A phase III clini-
cal trial is designed with relatively narrow patient inclusion
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and exclusion criteria in order to maximize the likelihood of
trial success and also to provide information that can inform
the product label. Phase III clinical trials will usually restrict
patient enrollment based on age, body size, renal and hep-
atic function, disease severity, and comorbidities. By defini-
tion, the phase III clinical trial population sample represents
only a fraction of the market population, and understandably
cannot accurately capture the diversity of patient charac-
teristics present in a heterogeneous patient population. The
lack of heterogeneity among enrolled patients is not explic-
itly described in the label; however, the FDA will place label
restrictions for “special populations” not adequately studied
(e.g., pregnancy/ lactation, pediatrics, geriatrics). While con-
siderable effort is now made to provide dosing information
for relevant drug interactions,12 children,13 and/or patients
with renal or hepatic impairment,14,15 it is uncommon for a
label to include well-defined dosing recommendations for
patients with functionally impactful genetic polymorphisms,
or for those who are pregnant/lactating, geriatric, or obese.
It is not required that either the sponsor or the FDA qualita-
tively and quantitatively describe the patient diversity differ-
ences between the phase III pivotal trial(s) sample and the
US anticipated market population.
The clinical and financial impact of precision dosing, while
not known for most drugs, is likely to be both significant
and measurable. In the United States adverse drug reactions
(ADRs) are known to be a leading cause of death and cost
billions of dollars in avoidable healthcare costs.16–18 Patient
populations that are at risk for ADRs include patients at the
extremes of age, those on multiple medications that may
interact with each other, and those with end-organ dysfunc-
tion, among others. Thus, the patients who are at greatest
risk for ADRs are often those who are not well represented in
phase III clinical trials. Furthermore, poor medication adher-
ence is estimated to result in avoidable costs of $105 billion
in the United States.19 The application of precision dosing
principles may help to reduce the incidence of preventable
ADRs related to inadequate dosage regimen selection and
plausibly improve medication adherence.
Today, prescribers commonly review electronic health
records (EHR) that contain information pertaining to the
patient’s age, body size, sex, clinical history, comorbidi-
ties, concomitant medications, and biomarkers. Ideally, the
patient’s clinical information would be integrated by a dos-
ing tool into a more precise dosing regimen for considera-
tion by the prescriber before the electronic prescription is
written. This approach to drug dosing would move clinical
practice towards a more patient-centered healthcare sys-
tem, which aligns with new value-based payment models
that expect providers to deliver health care that improves
patient outcomes and lowers the total costs of care.20 As pre-
viously noted,2 there are numerous examples where “model-
informed precision dosing” has been used to optimize drug
dosage regimens in individual patients;21–27 however, there
are barriers (e.g., integration of precision dosing tools into the
EHR) that need to be overcome before there is widespread
dissemination of available tools.3 Also, the capability to apply
precision dosing principles clinically through electronic pre-
scribing is generally not available for new, narrow therapeutic
index drugs, where serious consequences of under- or over-
dosing are present. Thus, there is a public health need to
create a paradigm shift in how drug dosing is optimized in
individual patients as part of the ongoing transformation of
health care.
CONSEQUENCES OF IMPRECISE DOSING
The lack of optimal dose selection during development often
impacts the sponsor by leading to phase III clinical trial fail-
ures, delayed market access (lost commercial opportunity),
and increased development expense.3,28 To decrease this
risk, drug sponsors continue to increase their time and mon-
etary investments in the identification and validation of pre-
dictive biomarkers and development of tools to increase the
probability of phase III clinical trial successes.6,29 Collection
of additional biomarker data is at the prerogative of the spon-
sor and is usually not a regulatory requirement. However,
biomarker and clinical end-point PK/PD and statistical analy-
ses enable the sponsor and regulators to gain a more precise
understanding of drug disposition and response. This is par-
ticularly true when only one drug dose is studied in phase III
pivotal trials, and when a new drug for a rare disease pro-
duces a weak efficacy signal. Cases exist where drugs have
been approved based on the insight provided by the drug
exposure–response relationship that could not otherwise be
seen (e.g., extended-release lamotrigine).9 Drug exposure–
response analyses that occur during NDA review are one
of the most important quantitative tools used to approve
new drugs. It would be useful if these same analyses were
used to help project dosing precision for the intended market
population.
Individual patients may experience maximal efficacy and
minimal toxicity when they receive a drug with a dosage
regimen optimally tailored to achieve a drug concentration
within the target therapeutic range. However, if the drug con-
centration achieved is too low at the prescribed dose due
to poor patient adherence, large body size, or metaboliz-
ing enzyme induction, for example, drug response may be
suboptimal and result in unintended outcomes (e.g., preg-
nancy despite appropriately prescribed oral contraception,
organ rejection or graft vs. host disease despite appropriately
prescribed immunosuppression), or even death, depending
on the drug and disease. Alternatively, unintentional over
dosage due to small body size, impaired renal function, or
a loss-of-function polymorphism in a metabolizing enzyme
may result in drug toxicities where the consequences could
range from simply bothersome symptoms, to more signifi-
cant morbidity, to death in extreme cases. Thus, there is an
unmet need to develop novel tools and strategies to optimize
drug dosage regimens with the specific intent of maximizing
both drug development successes (defined as a higher rate
of approvals), and also postapproval successes (defined as
maximal efficacy with minimal toxicity) when the drug will be
used in a more diverse patient population.
ELECTRONIC PATIENT CARE ENVIRONMENT
Nations have invested in creating an electronic patient care
environment to measure and improve healthcare quality
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Figure 1 Integration of electronic health record (EHR) data with computer provider order entry (CPOE) and clinical decision support (CDS)
tools.
(at both the individual and population levels), and to control
costs.30 In the United States, the Health Information Tech-
nology for Economic and Clinical Health (HITECH) Act was
passed in 2009, as part of the American Recovery and Rein-
vestment Act.31 One result of the HITECH Act, and associ-
ated funding ($27 billion over 10 years), was that by 2014,
97% of US hospitals possessed EHR software and 75% had
implemented EHRs.32 Similar statistics were found among
office-based physicians; in 2013, an estimated 78%of office-
based physicians used some type of EHR, an increase from
18% in 2001.33 The EHR, which is a digital version of a
patient’s chart, includes information such as patient demo-
graphics, diagnoses, laboratory results, procedures, medi-
cations, results of imaging studies, and clinician notes. The
EHR interfaces with applications that are important for the
delivery of patient care, including a computer provider order
entry (CPOE) system and clinical decision support tools. The
CPOE system allows the prescriber to select the treatment
regimen (drug, formulation, quantity, duration, and dosing
instructions), which is then recorded in the EHR, and simul-
taneously sent to the pharmacy where the medicine is dis-
pensed for the patient. Clinical decision support tools are
intended to help the clinician improve the quality of care for
each patient by using their personal information to improve
diagnosis and treatment accuracy and effectiveness. Soft-
ware components alignedwith the EHR should work together
seamlessly. For instance, one could imagine that when the
prescriber selects a treatment regimen in the CPOE system,
patient information in the EHR (e.g., diagnoses, age, weight,
laboratory values) could be aligned with prior best practice
knowledge embedded in the clinical decision support tools to
enable the prescriber to select the optimal drug and dosage
regimen, as well as provide information regarding clinically
important warnings for significant risks (Figure 1). The clin-
ician could also be reminded about the value of collecting
additional information (e.g., biomarker data) to make more
informed decisions. Several groups have pioneered the use
of model-based clinical decision support tools to facilitate
individualization of drug dosing.21,27,34–39
The main goal of the HITECH Act, which was implemented
in a staged manner, was to develop an electronic health-
care environment that improves individual healthcare qual-
ity and efficiency.32,40 This Act is intended to increase patient
engagement in their own health care, improve coordination
between healthcare providers and the patient, and control
costs. While healthcare quality is dependent on the health-
care provider’s skill and expertise, the new software environ-
ment embraces best practices that should benefit patients.
For example, if a prescriber is faced with an atypical patient
in their practice who has a disease or personal character-
istics that are not average (e.g., pregnancy, morbid obesity,
combination of factors), then a warning can be provided that
an “average” dose may be insufficient, which triggers dosing
and monitoring options for consideration.
www.cts-journal.com
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The functional software performance metrics have been
articulated by the federal government as a condition for
Medicare and Medicaid payments.31 There is competition
between companies to provide software products for EHR,
CPOE, and clinical decision support tools. The philosophy
is that the hospitals will provide the customization needed
to create the environment, dictated by local needs, policies,
and values. Competition has resulted in a demand for knowl-
edgeable professionals to build these products. However,
there is still an unmet need to develop and validate precision
drug dosing tools that can be integrated into these evolv-
ing technologies.3 Improving upon the new EHR environment
provides a unique opportunity for clinical pharmacologists
to play a pivotal role in shaping the future of precision dos-
ing. In addition, the largescale adoption of centrally stored
electronic health records, and the use of mobile applications
and wearable devices, provide an opportunity for patients to
be actively engaged in their health care outside the practice
setting.
DRUG CHARACTERISTICS WHERE PRECISION
DOSING IS IMPORTANT FOR THERAPEUTIC SUCCESS
Drugs that may benefit the most from precision dosing often
have one or more of the following characteristics: a narrow
therapeutic index; wide interpatient PK/PD variability; use
in high-risk patient populations; inadequate dosing that can
contribute to the development of disease resistance or tachy-
phylaxis; and/or high drug costs that burden patients, pay-
ers, and health systems. By definition, narrow therapeutic
index drugs require careful oversight, and there are exam-
ples of drugs where the doses/concentrations associated
with favorable efficacy outcomes or toxicities are not vastly
different.41,42 The liability or cost associated with imprecise
dosing can vary between drugs, but could include poor clin-
ical outcomes related to sub- or supratherapeutic exposure,
increased healthcare costs due to poor utilization of health-
care resources, and even death in extreme cases. While
we have roughly estimated that there may be several hun-
dred drug candidates for precision dosing, a more rigor-
ous analysis will include setting criteria and a process for
prioritization.43
Examples of drugs that exhibit some of these character-
istics are presented in Table 1. The examples are stratified
into three categories based on the level of evidence available
that supports the need for precision dosing. For example,
aminoglycosides are a class of antibiotics with a narrow ther-
apeutic index, and an example of a drug class where plasma
concentrations are measured routinely in order to facilitate
dose individualization. Subtherapeutic aminoglycoside con-
centrations can result in infection progression, treatment
failure, and may contribute to the emergence of resistant
bacteria, while supratherapeutic concentrations can cause
nephrotoxicity.44 As another example, the benefit of preci-
sion dosing has not been established clinically for most mon-
oclonal antibodies; however, precision dosing could poten-
tially help maximize drug efficacy and minimize toxicities, as
well as reduce the treatment costs of these drugs.34,45,46
As noted by Darwich et al.,2 ultimately, determination of
which drugs require precision dosing should include a sys-
tematic assessment of the patient and societal implications
of inadequate drug management on the patient, payers,
and the health system. In addition, the data and resources
required for the delivery of precision dosing should be con-
sidered. Evaluating the advantages and disadvantages of
precision dosing requires input from drug sponsors who
are knowledgeable about the drug, regulators who make
drug approval decisions based on benefit/risk considera-
tions, clinicians who are responsible for managing patients
and prescribing the drug, and payers who must make diffi-
cult decisions about how to use limited healthcare resources
most effectively. Manufacturers should have mechanisms in
place to update dosing guidelines as postmarketing surveil-
lance data become available. As previously suggested, this
information can be made available through “dynamic labels”
that are disseminated through available computer andmobile
software platforms and can be updated as new information
becomes available.2
Other obstacles that need to be considered include:
the establishment of therapeutic ranges and exposure–
response relationships, especially in the case of dosing
multidrug combinations (e.g., combination anticancer or
antiviral drug treatment) where there may be cases of over-
lapping therapeutic efficacy and adverse effects.2,45 Drug
plasma concentration and other biomarker assays will need
to be developed for routine use. These assays will need to
have acceptable accuracy and precision, a rapid turnaround
of results, and a reasonable cost so that they can be used
to adjust dosing. Finally, the ability to perform precision
dosing may be dependent on the availability of dosage
forms that could allow for dose individualization.2 For drugs
where intravenous or liquid formulations do not exist, limited
dosage strengths may be available, which will be a barrier
to implementation. As technology advances, development
of formulations that allow for individualization of drug dosing
will be important in order to facilitate precision dosing.
PATIENT POPULATIONS LIKELY TO BENEFIT FROM
PRECISION DOSING
The need for precision dosing requires consideration of the
patient population to whom the drug is prescribed. As pre-
viously noted, drugs often are tested in clinical trials that
enroll homogenous patient cohorts. If the drug is approved,
there may be widespread use in patient populations where
limited/no data are available to determine optimal dosing.
The need for precision dosing may be greater in these patient
populations because ofmore pronounced interpatient PK/PD
variability, which could result in altered efficacy and safety
profiles. Because the underlying disease process and/or
exposure–response relationship of drugs used in these spe-
cial populations may differ from the population originally
studied, additional clinical trials are typically needed in order
to assess PK/PD and develop the appropriate mathematical
models that can be used to devise more precise dosage regi-
mens. Pediatric and geriatric patients are examples of patient
populations that are likely to benefit from the application of
precision dosing principles, particularly for drugs with a nar-
row therapeutic index, due to changes in drug disposition
and/or effects.47,48 Precision dosing in special populations
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Liability (potential consequences that may occur with
supra- and/or subtherapeutic concentrations)






Subtherapeutic: emergence of resistant bacteria, lack of
resolution of infection, and sepsis
Cardiac inotrope Digoxin80 Altered renal function and
geriatrics
Supratherapeutic: Cardiac-related toxicity can include
ventricular tachycardia, ventricular ectopic beats, and
2nd or 3rd degree atrioventricular block.
Noncardiac toxicity can include confusion and abnormal
color vision.
Alkylating agent (cell cycle
nonspecific)
Busulfan81 Pediatric and adult
HSCT patients
Supratherapeutic: hepatotoxicity (i.e., VOD and SOS) and
pulmonary toxicity
Subtherapeutic: inadequate myeloablative chemotherapy
and graft vs. host disease
Calcineurin inhibitors Cyclosporine,
tacrolimus82,83
Pediatric and adult HSCT
and solid organ
transplant patients
Supratherapeutic: acute and chronic nephrotoxicity,
hyperglycemia, and neurotoxicity (insomnia, seizure,
tremors)
Subtherapeutic: graft vs. host disease (HSCT) and graft




Warfarin84 Gene variant carriers
(CYP2C9, VKORC1),
geriatrics, and those at
risk for drug–drug
interactions
Supratherapeutic: high INR (increased risk of bleeding)




Efavirenz85–87 Gene variant carriers
(CYP2B6)
Supratherapeutic: neuropsychiatric effects (dizziness,
nightmares, insomnia, nervousness, cognitive
dysfunction, depression, suicide ideation, and anxiety)
Subtherapeutic: inadequate exposure leading to the
development of viral resistance








HR+ BC, NET, RCC,




Polymyxins Polymyxin B90 Critically ill patients Supratherapeutic: nephrotoxicity, neurotoxicity
Subtherapeutic: inadequate exposure resulting in







Altered renal function and
those at risk for
drug–drug interactions
Supratherapeutic: increased risk of bleeding
Subtherapeutic: increased risk of thrombosis








Selective BCL-2 inhibitor Venetoclax97–100 Those at risk for
drug–drug interactions
Supratherapeutic: tumor lysis syndrome (ramp-up phase)
HSCT: hematopoietic stem cell transplant; VOD: veno-occlusive disease; SOS: sinusoidal obstruction syndrome; CYP2C9: cytochrome P450 2C9; VKORC1:
vitamin K epoxide reductase complex subunit 1; INR: international normalized ratio; CYP2B6: cyptochrome P450 2B6; mTOR: mammalian target of rapamycin;
Advanced HR+ BC: advanced hormone receptor-positive, HER2-negative breast cancer; NET: advanced neuroendocrine tumors; RCC: advanced renal cell
carcinoma; TSC: renal angiomyolipoma with tuberous sclerosis complex; SEGA: subependymal giant cell astrocytoma; TKI: tyrosine kinase inhibitor; CDK: Cyclin-
dependent kinase; BCL: B-cell lymphoma.
aAdditional studies are needed to demonstrate the value of therapeutic drug monitoring in nontransplantation settings.88
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also requires consideration of practical and logistical factors,
including low neonatal blood volumes that limit the collection
of PK samples.
AVAILABLE TOOLS TO FACILITATE PRECISION DOSING
Precision dosing requires clinical tools that can translate an
individual’s genotypic and phenotypic characteristics into an
individually tailored dosage regimen. Two fundamental ele-
ments are critical in this translation. The first element is to
discover and establish genotypic and phenotypic biomark-
ers that can either accurately reveal a patient’s disease sta-
tus or reliably predict therapeutic outcomes.49 A second ele-
ment is to develop and validate quantitative clinical deci-
sion support tools that translate predictive dosing models
to individual patient dosing selection. These two compo-
nents are both imperative for developing and implement-
ing a precision dosing strategy for prospective evaluation,
and they are interdependent on each other for aiding clinical
decisions.
Genetic variants have been applied broadly as biomark-
ers to either stratify patients or select an appropriate ther-
apy, dose, or regimen. Tailoring the selection and dosing
of therapies for specific gene variants is a well-recognized
but an underutilized approach.50 Genetic variants in drug-
metabolizing enzymes or transporters can significantly alter
PK/PD, and dosing adjustments may be advised depend-
ing on metabolizer or transporter status.51 A key challenge
in validating genetic biomarkers is to identify which of the
many variants are “drivers” or actionable markers. Improved
evidence-based modeling approaches are needed to make
genetic information available at the time of prescribing if clin-
icians are to use these in routine patient care. In addition to
genomic biomarkers, the use of transcriptomic, proteomic,
and metabolomic methods may also allow for better tailoring
of drug treatment.52–55
Phenotypic biomarkers, particularly those that significantly
predict drug PK/PD, are important for precision dosing. For
drugs with a narrow therapeutic index, plasma or blood
drug concentrations are often monitored. Therapeutic drug
monitoring (TDM), also known as adaptive feedback con-
trol, is a commonly applied strategy to incorporate real-
time drug concentrations into dosing considerations to con-
strain concentrations within a target window.56 Also, many
broader phenotypic characteristics of patients (e.g., age,
renal function, body size), have been used to tailor individual
therapy when relevant. While genetic biomarkers are static
but variable in prevalence within a population, phenotypic
biomarkers (patient characteristics) are dynamic and may
change rapidly within a patient (e.g., creatinine clearance)
with high inter- and intraindividual variabilities. This diversity
and extensive variability in patient characteristics is not suf-
ficiently represented in typical phase III trials, where there
are reasonable attempts to constrain variability. Therefore, to
implement precision dosing, tools should be widely devel-
oped, validated, and implemented, which enable the iden-
tification and quantitative characterization of the sources of
patient variability.2,3 For instance, if a patient has been stable
while receiving digoxin to treat congestive heart failure, but
serum creatinine concentrations have been increasing over
recent clinic visits, then the clinical decision support system
could trigger a warning to the prescriber to consider measur-
ing the digoxin serum concentration, which could possibly
lead to dose reduction and toxicity mitigation. Also, preci-
sion dosing recommendations should be simplified to focus
on those phenotypic variables that are expected to have a
significant impact on dosing.
There are many quantitative tools and methods avail-
able that can be used to characterize and account for
sources of PK/PD variability. For example, nonlinear mixed
effects modeling (i.e., population modeling),57,58 physiolog-
ically based PK/PD (PBPK/PD) modeling,59 and Bayesian
methods are used widely to characterize drug disposition
and effects.2,60 These methods are implemented in com-
monly used and commercially available software packages
for data analysis.61,62
Population PK/PD models create the basis for individ-
ual patient dose adjustments with the goal of achiev-
ing a target drug plasma concentration range associ-
ated with efficacy and safety. These models provide the
relationship between drug concentration and effect, while
identifying patient covariate characteristics from clinical
studies both prior to NDA approval and thereafter.57,58
Population PK/PD modeling can support precision dosing
in several ways, including covariate-based a priori dos-
ing and TDM-based a posteriori dosing. Covariate-based
a priori dosing involves dose selection based on patient
factors that have been identified as important predic-
tors of interindividual variability in PK/PD parameters.63
TDM-based a posteriori dosing involves covariate-based
a priori dosing followed by dose individualization through
assessment of drug concentrations or effects, and appli-
cation of Bayesian methods to estimate individual PK/PD
parameters.63–65 Various tools have been developed to facil-
itate dose optimization through Bayesian adaptive control
methods, including InsightRx (http://insight-rx.com/), TDMx
(http://www.tdmx.eu/), DoseMe (https://doseme.com.au/),
and BestDose (http://www.lapk.org/bestdose.php), among
others. The history and evolution of the application of
Bayesian methods in clinical decision support tools has been
reviewed previously.66,67
When faced with determining dosing recommendations for
new drugs in patients not studied in pivotal trials, it is pos-
sible to use prior knowledge of other drugs that have similar
physicochemical and PK/PD characteristics. PBPK models
represent a systems mass balance modeling approach that
allows for a mechanism-based PK analysis.59 PBPK model-
ing can be used to project an initial dose for these patients
that will need confirmation in prospective clinical studies.2 In
addition, PBPK models can be used in predicting PK when
multiple characteristics are known to alter drug disposition
or efficacy.10 A major advantage of PBPK modeling is the
ability to integrate knowledge from human physiology, drug
physicochemical properties, and enzyme and protein vari-
ability in patients to generate drug PK predictions in a
given population or individual. PBPK models also have
been applied broadly to guide individual dosing in special
populations.68,69 PBPK models can also support precision
dosing in a variety of clinical settings, including patients
with organ dysfunction, patients coadministered enzyme
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Figure 2 Bridging information, including exposure–response relationships, from the original patient population studied in clinical trials to
specific populations that will receive the drug in real-world clinical practice.
inhibitors and inducers, and populations with certain genetic
variations.
FACILITATING PRECISION DOSING IN NEW PATIENT
POPULATIONS
Once a drug has been approved by a regulatory body, addi-
tional clinical trials may be needed in patient subgroups that
are likely to benefit from a dosage regimen different from the
standard dosing paradigms derived from phase III efficacy–
safety outcomes data. These studies can focus on charac-
terizing PK alone, PK/PD, efficacy, and/or safety of the drug
in a new patient population.
The initial drug label at the time of FDA approval invari-
ably possesses many gaps in drug dosing for specific patient
populations, and it can oftentimes be years before they are
addressed. The dosing gaps include common variables (e.g.,
organ failure, body size, age extremes), as well as less com-
mon variables (e.g., pregnancy, severe burns), all of which
can profoundly change dosing requirements. Today, clini-
cians treating patients who present with a complex combi-
nation of common and uncommon variables are left to their
own ingenuity to estimate dosing.
Prior knowledge of the drug can be used to inform the drug
development programs in these new patient populations.70
For example, a sponsor may decide to pursue a pedi-
atric drug development program if a drug is likely to be
used in children. Full or partial extrapolation of efficacy
from well-controlled studies performed in adults may be
allowed, depending on the similarity of disease processes
and exposure–response relationships.13 In the case of full
extrapolation, the pediatric drug development program is
focused on identifying a pediatric dose that achieves com-
parable drug exposure to that observed in adults, and eval-
uating the safety of the drug at the selected dose.
Thus, in selecting the optimal strategy for developing dos-
ing regimens for special populations, a decision should be
made whether to perform a new clinical efficacy–safety trial
or to match drug concentration exposure in the special
patient population to historical values from the pivotal phase
III trial. As shown in Figure 2, this requires consideration of
similarities in the exposure–response relationship and dis-
ease processes in the special population relative to patients
enrolled in the pivotal phase III trials. Since the cost is much
greater to perform a new clinical trial to demonstrate effi-
cacy and safety, bridging and application of model-based
approaches may be an acceptable strategy to aid in dose
selection until evidence indicates the need to justify the costs
of conducting a clinical study.2,71
PROPOSED PRECISION DOSING DEVELOPMENT
FRAMEWORK
A precision dosing strategy can be established for new drugs
under development, or after regulatory approval. For the for-
mer, the sponsor and regulatory agencies could begin to con-
sider whether a new drug is likely to require precision dosing
at the time of approval of an Investigational New Drug (IND)
application. The drug characteristics were discussed earlier
in this article. We also believe that development and approval
strategies (e.g., dose finding, phase III patient population,
study end points) can be considered. If either the sponsor
or the regulatory agency believe this new drug is a candidate
for precision dosing, then the clinical development pathway
can be designed to better define exposure–response rela-
tionships, and characterize responders and nonresponders
using biomarkers during both early and late phase develop-
ment. An early phase II regulatory decision could be made
to help assure adequate biomarker and PK/PD assessments
are performed in phase II/III studies.
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We believe, as others have suggested, that a new
postregulatory approval process is needed to support pre-
cision dosing for relevant marketed drugs.2,3 We propose
that this process could be separated into three phases: i)
prior knowledge aggregation, ii) precision dosing studies
and design, and iii) clinical decision support tool design,
qualification, and implementation.
Prior drug-disease knowledge needs to be aggregated
to facilitate data sharing. The pharmaceutical industry has
begun to make some progress on this front by outlining
their commitment to the responsible sharing of clinical
trial data.2,72 Information types includes patient-level, de-
identified phase IIb and phase III clinical trial data, previously
developed population and PBPK/PD models, and informa-
tion regarding relevant predictive biomarkers associated
with patient outcomes. Also, the model code and biomarker
assay data should be made publicly available to assure that
scientists can accurately reproduce the pivotal analyses. The
phase IIb and phase III data also may be used to generate a
larger postmarket database, upon which subsequent preci-
sion dosing models can be created. For drugs with multiple
indications, such as anticoagulants (e.g., stroke prevention
in atrial fibrillation, deep vein thrombosis prophylaxis), infor-
mation on all end points will be needed to generate precision
dosing recommendations within various subgroups. For
patient subgroups where data that would allow for precision
dosing are lacking, additional data can be collected through
prospective studies; for example, opportunistic protocols
that capitalize on standard of care procedures for patients
already receiving a drug of interest can be used to efficiently
collect PK/PD data in special populations.73
Multistakeholder collaborations will be important to val-
idate, implement, and demonstrate the value of precision
dosing tools. Academic institutions and disease centric orga-
nizations, such as the American Heart Association and Amer-
ican Cancer Society, can be pivotal for developing precision
dosing strategies, postapproval, in collaboration with the
sponsor. In the United States, academic institutions affiliated
with the Clinical and Translational Science Awards (CTSA)
program (https://ncats.nih.gov/ctsa) can collaborate to eval-
uate the use of precision dosing tools across multiple sites.
Funding can be pursued by these groups from the govern-
ment, the pharmaceutical industry, and/or private founda-
tions to conduct the requisite studies needed to develop,
refine, and validate precision dosing strategies, and then
to implement those strategies in clinical decision support
tools. Unfortunately, for drugs that already have regulatory
approval, there may be the perception that these necessary
studies represent only incremental progress and this work
may receive a low priority funding score. The justification to
fund this work is to create an efficient decentralized process
for rapidly selecting precision dosing candidates, and col-
lecting the clinical information in large, diverse patient pop-
ulation samples upon which drug dosing models and tools
can be validated and implemented. The need to create bet-
ter dosing for all patients is similar to establishing the Sentinel
system to provide rapid accurate postmarket safety infor-
mation for medical products.74 In these studies, the num-
ber of patients enrolled can be based on an assessment
of the drug’s therapeutic index, expected PK/PD variabil-
ity, disease severity/lethality and prevalence/penetrance, as
well as the logistical factors that can affect patient enroll-
ment and study design. The data collected from these stud-
ies can be analyzed with and without the premarket patient
data to create a population PK/PD model for all patients.
Based on the results of the prospective study, clinician
groups with direct knowledge of the patient population under
study can propose optimal dosing regimens that can then be
implemented.
Approved precision dosing recommendations will need to
be converted into a drug-specific precision dosing tool for
incorporation into clinical decision support software or the
EHR itself. As noted by Darwich et al., development of a
“companion tool” can begin early in the drug development
process.2 We also believe that integration of precision dos-
ing tools into the EHR itself will be critically important in
order to ensure their widespread use.3 Whether the tools are
open source or proprietary will depend on the funding model.
During the clinical implementation processes, the functional-
ity and usability of the tools, as well as prescriber acceptance
of the dosing recommendations, must be evaluated. These
implementation studies can culminate in the development of
a “playbook” that would allow for widespread dissemination
of the most optimal use of the precision dosing tool. Gover-
nance procedures need to be established to help assure tool
quality, but also provide for local customization as needed.
There should be iterative and adaptive processes for continu-
ous refinement and quality improvement of the precision dos-
ing tool. Because the majority of drugs are marketed glob-
ally, data pertaining to optimal drug dosing should be made
publicly available to allow for widespread use of these tools,
and of precision dosing strategies. For drugs developed pri-
marily for use in only one global region (e.g., United States
or Europe), it would be possible to use prior knowledge and
experience to predict dosing among populations in another
global region (e.g., Asia or Africa). Subsequent confirmatory
studies, designed for further tool refinement, could highlight
important dosing differences between distinct patient popu-
lations. For some drugs, particularly where TDM is available,
precision dosing tools could evolve to allow patients to pro-
vide feedback directly to their prescriber so that enhanced
patient–prescriber communications could identify a need for
dose adjustments.
Depicted in Figure 3 is a systematic process for the devel-
opment, validation, and implementation of precision dosing
tools. The process begins with an assessment of the gap
between the phase III trial and market population, which may
result in conducting a large (e.g., N > 1,000) PK/PD study
designed to evaluate the drug characteristics in patient sub-
groups not enrolled in phase III trials. The total sample size
and number of patients enrolled from each relevant special
population need to be quantitatively justified. These data will
aid in the development of a PK/PD model that can facilitate
dosage regimen individualization. As suggested by others,2,3
this tool may need to be validated and refined prior to imple-
mentation. We recommend that this assessment culminate
in the generation of a report that can help to facilitate dis-
cussions with expert clinician groups. Ultimately, the model
and associated recommendations would be published for
widespread evaluation and use.
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Figure 3 Drug dosing tool development process. Pharmacokinetic (PK) / pharmacodynamic (PD) studies in the market population can
be performed, if needed. Using the information collected in these studies and/or prior information, optimal dosing regimens are designed
for all patients. These dosing regimens are then implemented in clinical decision support (CDS) tools. Use of this dosing information and
tool is then evaluated, and there is a process in place for continuous refinement and quality improvement of the dosing tool.
In the United States, both the FDA Center for Drug Evalu-
ation and Research (CDER) and the Center for Devices and
Radiologic Health (CDRH) may play a role in this process.
Drug information and analyses performed during regulatory
(CDER) approval decisions will be useful in providing a basis
for recognizing which new drugs will benefit from precision
dosing as well as a quantitative source for tool development.
It may be that CDER scientists will wish to have access
to precision dosing drug databases for subsequent label-
ing purposes. While CDRH can regulate medical software,
there will be a need to clarify whether precision drug dos-
ing software will require premarket approval. The precision
dosing development process outlined in Figure 3, includ-
ing qualification testing and a published report, will be useful
for these discussions with regulators. Legal liability is uncer-
tain for clinical decision support software and patient support
software applications.75,76 The commitments to verify soft-
ware prediction accuracy and continuously improve quality
may help limit liability.
ANTICIPATED IMPACT
The aforementioned proposed changes, supporting preci-
sion dosing for relevant drugs, should maximize medication
efficacy and minimize medication toxicities. Precision dosing
could also plausibly increase adherence as drug efficacy
increases and toxicity decreases, resulting in decreased
healthcare costs. Sponsors should benefit, in that their
products will have an improved efficacy/safety profile. Regu-
latory agencies may also benefit because more patients will
be better served and their internal analyses can be useful
beyond the approval and labeling decisions. As recom-
mended in this article and others,2,3 prospective studies in
real-world patient populations, including randomized trials,
should be conducted to determine the effect of the precision
dosing tool on relevant patient outcomes and behaviors,
such as adverse drug events and medication adherence.
Further, studies also should evaluate the implementation
and validation of the tool, its potential for dissemination, and
its associated costs to the healthcare system. Prospective
health economic analyses are needed in order to demon-
strate the value of precision dosing tools. We believe that
these analyses will be important as healthcare systems
move toward new value-based payment models.20
In the United States and other parts of the world, there
has been an increase in the use of centrally stored electronic
health records, which facilitate the implementation of preci-
sion dosing. Patient data are now available to inform preci-
sion dosing tools, and clinical decision support systems are
being developed to allow prescribers to more precisely and
safely use drugs. Knowledge gaps will emerge and can be
quickly addressed as clinical implementation of these tools
becomes routine. The system by which precision dosing is
delivered should allow dosing regimens to be continuously
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reevaluated and improved as needed. Regulatory agencies
and the sponsor can provide the necessary information
for this postmarket system, while clinicians, academic sci-
entists, and other research organizations should establish
themselves as standard-bearers for development, validation,
and implementation of precision dosing tools and strategies.
Ultimately, the development of these precision dosing strate-
gies will decrease healthcare costs, improve the efficiency of
drug development, and address a significant public health
need.
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